10.04 0 (0%) | 04-26 15:14 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 11.79 | 1-year : | 11.85 |
Resists | First : | 10.1 | Second : | 10.14 |
Pivot price | 10.04 | |||
Supports | First : | 10.02 | Second : | 8.33 |
MAs | MA(5) : | 10.03 | MA(20) : | 10.05 |
MA(100) : | 10.06 | MA(250) : | 9.98 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 32.5 | D(3) : | 24.5 |
RSI | RSI(14): 33.6 | |||
52-week | High : | 10.25 | Low : | 9.86 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EUCR ] has closed above bottom band by 43.2%. Bollinger Bands are 91.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 10.06 - 10.11 | 10.11 - 10.15 |
Low: | 9.9 - 9.97 | 9.97 - 10.02 |
Close: | 9.94 - 10.05 | 10.05 - 10.13 |
Eucrates Biomedical Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses to identify and acquire a business in the biomedical or healthcare-related industries in North America and Europe. The company was incorporated in 2020 and is based in New York, New York.
Tue, 11 Apr 2023
Eucrates Biomedical Acquisition Corp. Announces Liquidation - PR Newswire
Tue, 27 Jul 2021
AdTheorent Going Public with MCAP Acquisition (MACQ) - TheStreet
Tue, 20 Jul 2021
CCIV Rises Ahead of Lucid Vote, Reminds to Vote - TheStreet
Fri, 25 Jun 2021
Churchill (CCIV) & Lucid Sets its Vote Date - TheStreet
Mon, 14 Dec 2020
Eucrates Biomedical Acquisition Corp. Announces The Separate Trading Of Its Ordinary Shares And Redeemable ... - BioSpace
Thu, 05 Nov 2020
SPACs Soar as Fast, Hassle-Free IPO Alternatives for Biotech Companies - BioSpace
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Financial Services
|
|
Industry:
Shell Companies
|
|
Shares Out | 4 (M) |
Shares Float | 2 (M) |
Held by Insiders | 62.2 (%) |
Held by Institutions | 9.1 (%) |
Shares Short | 1 (K) |
Shares Short P.Month | 1 (K) |
EPS | 0.2 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -0.88 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | 0 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 22.7 % |
Operating Cash Flow | -1 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | 47.8 |
PEG Ratio | 0 |
Price to Book value | -11.41 |
Price to Sales | 0 |
Price to Cash Flow | -67.07 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |